Goldman Sachs Physical Gold ETF vs Abeona Therapeutics Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.4, while Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M). The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | ABEO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $7.45 |
52-Week Low | $32.74 | $4.17 |
Market Cap | — | $424.33M |
Enterprise Value | — | $279.23M |
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $42.81, up 2.22% in the past 24 hours. Technical indicators show a bullish overall signal with strong moving average support, though oscillators suggest caution due to overbought RSI levels. Recent news highlights gold's rebound potential, with analysts citing supportive factors like central bank buying and easing Fed expectations as catalysts for further price appreciation.
The outlook for AAAU remains positive, driven by gold's strategic role amid geopolitical and fiscal uncertainties. Key risks include potential Fed policy shifts and market volatility, but institutional accumulation and bullish analyst forecasts indicate sustained investor confidence in gold's upward trajectory.
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Trailing returns across standard periods
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →